A Study of SHR6390 in Advanced Solid Tumor Patients

NCT ID: NCT02684266

Last Updated: 2022-07-11

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 40 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2016-03-03
• Study Completion Date: 2019-06-28

Brief Summary

SHR6390 is a small molecular, oral potent, selective CDK4/6 inhibitor. The purpose of this study is to investigate the safety/tolerability and the pharmacokinetic profile of SHR6390 in Chinese advanced solid tumor patients by using a "3+3" dose escalation.Preliminary efficacy will be also investigated in this study.

Conditions

Neoplasm

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

SHR6390

Each subject will receive a single dose of SHR6390 and then repeat doses following a 3 week/1 week off regimen

Group Type: EXPERIMENTAL

SHR6390

Intervention Type: DRUG

SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD

Interventions

SHR6390

SHR6390 either 25, 50mg, 75mg, 100mg, 125mg, 150mg, 175mg given orally, QD

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Pathologically confirmed solid tumor and failed from all standard treatment
• Eastern Cooperative Oncology Group (ECOG) performance status: 0-1
• Life expectancy ≥ 3 months
• Adequate function of major organs, meaning the following criteria should be met within 14 days before randomization:

• Hemoglobin > 110g/L
• Neutrophils > 2.0×10^9/L
• Platelets > 100×10^9/L
• Total bilirubin < 1.5×the upper limit of normal (ULN)
• ALT and AST ≤ 1.5×ULN (≤ 5×ULN, if existing liver metastases)
• Creatinine ≤ 1 ULN
• Left ventricular ejection fraction (LVEF) ≥ 50%
• QTcF(Fridericia correction) male≤450 ms, female≤470 ms
• Good compliance of patient by physician's judgement
• Signed and dated informed consent

Exclusion Criteria

• Previously received therapy of anti-tumor agent targeting at CDK4/6
• Less than 3 weeks from the last cell-toxicity chemotherapy, less than 6 weeks from last mitomycin or nitrosamine therapy
• Less than 3 weeks from any other anti-tumor therapy (including targets therapy, immunotherapy or other approved therapy)
• Having joined in other clinical trials within 4 weeks
• Uncontrolled/untreated brain metastasis (well-controlled/well-treated brain metastasis by physician's judgement is allowed)
• existing abnormal CTCAE≥grade 2 resulted from previous treatment(except grade 2 alopecia)
• uncontrollable symptomatic pleural effusion or ascites or require clinical intervention
• require continous treatment by steroids
• Factors influencing the usage of oral administration (e.g. unable to swallow, chronic diarrhea and intestinal obstruction, etc.)
• existing uncontrollable hypokalemia or hypomagnesemia
• history of serious allergy events or known being allergy constitution
• active HBV or HCV infection (HBV virus≥10e4 copies/ml, HCV virus≥10e3 copies/ml)
• History of immunodeficiency, acquired or congenital immunodeficiency, history of organ transplantation
• history of cardiac dysfunction, include(1)angina (2)clinical significant arrythmia or require drug intervention (3)myocardial infarction (4)heart failure (5) other cardiac dysfunction (judged by the physician); any cardiac or nephric abnormal ≥grade 2 found in screening
• Female patients who are pregnancy, lactation or women who are of childbearing potential tested positive in baseline pregnancy test childbearing female who refuse to accept any contraception practice
• determined by the physician, any coexisting disease might lead to life threatening complications or avoid the patients from accomplishing the treatment(e.g serious hypertension, diabetes, thyroid dysfunction,etc.)
• history of neuropathy or dysphrenia, including epilepsy and dementia

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Jiangsu HengRui Medicine Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Binhe Xu, M.D

Role: PRINCIPAL_INVESTIGATOR

Cancer Hosptial, Chinese Academy of Medical Sciences

Locations

Cancer Hospital, Chinese Academy of Medical Sciences

Beijing, , China

Countries

China

References

Zhang P, Xu B, Gui L, Wang W, Xiu M, Zhang X, Sun G, Zhu X, Zou J. A phase 1 study of dalpiciclib, a cyclin-dependent kinase 4/6 inhibitor in Chinese patients with advanced breast cancer. Biomark Res. 2021 Apr 12;9(1):24. doi: 10.1186/s40364-021-00271-2.

Reference Type: DERIVED

PMID: 33845905 (View on PubMed)

Other Identifiers

SHR6390-I-101

Identifier Type: -

Identifier Source: org_study_id